|
|
Volumn 17, Issue 8, 1999, Pages 755-757
|
|
Therapeutic peptides revisited
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTIVIRUS AGENT;
CONXN;
DEPREOTIDE TC 99M;
EPTIFIBATIDE;
GASTRIMMUNE;
LUCINACTANT;
NEW DRUG;
PEPTIDE;
PEXIGANAN ACETATE;
POLYPEPTIDE ANTIBIOTIC AGENT;
RECOMBINANT PROTEIN;
RETICULOSE;
SURFACTANT;
SYNTHETIC PEPTIDE;
TEDUGLUTIDE;
THYMOSIN ALPHA1;
UNCLASSIFIED DRUG;
BIOTECHNOLOGY;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG DEGRADATION;
DRUG DELIVERY SYSTEM;
DRUG FORMULATION;
DRUG INDICATION;
DRUG MANUFACTURE;
DRUG RESEARCH;
DRUG STABILITY;
DRUG SYNTHESIS;
GENETIC RECOMBINATION;
HUMAN;
IMMUNOGENICITY;
PEPTIDE SYNTHESIS;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
SOLID PHASE EXTRACTION;
TRANSGENE;
CLINICAL TRIALS;
DRUG DESIGN;
DRUG STABILITY;
HUMANS;
PEPTIDES;
RECOMBINANT PROTEINS;
TRANSGENES;
|
|
EID: 0032877184
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/11686 Document Type: Review |
|
Times cited : (193)
|
|
References (2)
|
